Mesoblast Ltd

MESO

Company Profile

  • Business description

    Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

  • Contact

    55 Collins Street
    Level 38
    MelbourneVIC3000
    AUS

    T: +61 396396036

    E: [email protected]

    https://www.mesoblast.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    73

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,772.001.00-0.01%
CAC 407,662.593.32-0.04%
DAX 4023,673.29236.32-0.99%
Dow JONES (US)44,575.47480.701.09%
FTSE 1008,785.3324.370.28%
HKSE24,072.28211.87-0.87%
NASDAQ20,240.17129.57-0.64%
Nikkei 22539,986.33501.06-1.24%
NZX 50 Index12,734.53131.711.05%
S&P 5006,206.321.370.02%
S&P/ASX 2008,541.101.20-0.01%
SSE Composite Index3,444.4320.200.59%

Market Movers